Clinical Trial Update: An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years [Phase 3]

View source ↗

Summary

Phase 3b open-label randomized study in chronic myeloid leukemia investigating confirmed molecular response rate over two years; trial terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Snippet

Sponsor: Prof. Dr. Nikolas von Bubnoff | Conditions: Chronic Myeloid Leukemia | Phase 3 | Status: TERMINATED